The progress made by the operational expansion is evidenced by these finals to June 2025, which report a 46% increase in Revenue to £0.83m. The loss before tax decreased 32% to £0.457m and year end cash is £0.461m. We assume the accelerating trading momentum its maintained, suggesting a 10-12month cash runway at the lower burn rate. Following the appointment of a Head of Quantitative Pharmacology and a Head of Biometrics, the Company has further invested in business development and marketing, w ....